Skip to main content

Table 3 Patient characteristics at each assessment point

From: Shared decision-making in antihypertensive therapy: a cluster randomised controlled trial

  Intervention group Control group
  T0 T1 T2 T3 T0 T1 T2 T3
Number GP practices 17 17 17 17 19 19 18 18
Primary endpoints         
SDM-Q-9         
 Total valid Nr 451 363 333 301 489 368 295 269
 Mean 73.00 73.03 70.51 71.71 70.67 66.55 67.20 66.60
 (SD) (17.66) (19.54) (20.98) (20.59) (20.24) (21.34) (20.00) (20.71)
Systolic BP         
 Total valid N 552 463 418 383 568 457 394 348
 Mean in mmHg 133.19 128.86 129.27 128.68 130.80 126.98 126.62 125.98
 (SD) (13.58) (12.51) (12.80) (11.42) (12.62) (11.75) (12.29) (11.23)
Secondary endpoints         
Diastolic BP         
 Total valid N 552 463 418 383 568 457 394 348
 Mean in mmHg 81.98 79.21 79.07 78.55 79.29 76.75 76.75 75.64
 (SD) (9.77) (9.49) (8.79) (8.81) (9.74) (9.10) (9.10) (8.46)
CVR         
 Total valid N 420 364 320 312 377 336 270 233
 Mean in % 20.40 21.02 22.33 23.92 22.85 23.54 24.03 24.34
 (SD) (18.15) (18.61) (18.82) (19.10) (18.71) (19.19) (19.23) (19.60)
MARS-D         
 Total valid N 531 419 387 349 539 408 357 326
 Mean 93.9 95.4 96.0 96.1 93.5) 96.0 96.1 95.3
 (SD) (9.8) (8.8) (6.8) (8.0) (10.1) (6.3) (6.8) (7.5)
Knowledge 536 455 412 371 547 444 382 343
 Total valid N 536 455 412 371 547 444 382 343
 Mean 46.63 50.05 50.18 53.34 44.22 47.04 47.64 48.51
 (SD) (27.60) (28.39) (28.32) (28.21) (28.64) (30.11) (30.49) (30.15)
  1. BP Blood Pressure, SDM-Q-9 Shared Decision Making-Questionnaire, CVR cardiovascular risk, MARS-D Medication Adherence Report Scale-German Version.